(NewsDirect)
Race Oncology Ltd(ASX:RAC) CEO and managing director Damian Clarke-Bruce speaks withProactive soon after launching a new corporate strategy focused onmaximising bisantrene’s anti-cancer and cardio-protectivepotential.
Thecompany’s lead clinical focus will be on investigating anti-cancer,plus cardio-protective and FTO (fat mass and obesity-associatedprotein) properties in metastatic breast cancer, using theperipherally administered bisantrene formulation, RC220 with a view toimproving therapeutic outcomes and heart health for patients withcancer.
Clarke-Bruce said: “Race’s revised development program hasbeen designed in such a way that our new bisantrene formulation canfit straight into a global pharmaceutical partner'spipeline.
“Through our rigorous clinical development plan, Race willinvestigate bisantrene RC220 in both metastatic breast cancer andcontinue our clinical experience in AML, while investigating andexpanding our knowledge of its mechanism of action.
“We have a clear regulatory pathway and aprogram that is supported by international key opinion leaders, for adrug candidate which has already been shown to improve patients’lives.”
ContactDetails
Proactive Investors
GreggCastano
+1 203-762-5649
Copyright (c) 2023 TheNewswire - All rights reserved.